Gestación prolongada asociada con la prescripción inadecuada de medroxiprogesterona acetato. ¿Es racional y ético el uso de progestágenos exógenos en perras?

Authors

  • María S. González D.
  • Juan Guillermo Maldonado Estrada

DOI:

https://doi.org/10.17533/udea.rccp.324103

Keywords:

distocia, maceración.fetal, monta.indeseada, progestágenos

Abstract

Resumen

Los progestágenos sintéticos como la medroxiprogesterona acetato (MPA) y el proligestone (PRO) son usados en caninos como medicamento para prevenir la presentación del celo en perras, a pesar de existir abundante evidencia de su asociación con el aumento de la presentación de tumores mamarios y uterinos, complejo hiperplasia quística endometrial-piómetra  y alteraciones de la hormona del crecimiento que cursan con acromegalia. En el presente estudio se informa de un caso de gestación prolongada asociada con la administración de MPA para prevenir la gestación después de una monta no deseada, en una perra de raza Fox terrier pelo de alambre de cinco años de edad a quien se le prescribió de manera errónea MPA para la monta no deseada. La paciente se recibió a los 74 días postmonta, con abdomen distendido pero sin dificultad respiratoria ni cambios importantes en el hemoleucograma; el examen clínico y la radiografía revelaron la presencia de seis fetos en proceso de maceración; la paciente fue sometida a operación cesárea para la extracción de los fetos macerados seguida de ovariohisterectomía. La evolución clínica fue favorable. En la discusión se hacen unos planteamientos críticos sobre la racionalidad y la ética del uso de los progestágenos exógenos, al igual que de la aplicación de productos estrogénicos, para el control de eventos reproductivos en perras, como la monta no deseada o la supresión del celo, y se proponen otras alternativas terapéuticas.

Palabras clave: distocia, maceración fetal, monta indeseada, progestágenos.

Summary

Medroxiprogesterone acetate (MPA) has been commonly used as a contraceptive in bitches by its effect on preventing estrous presentation, instead of abundant evidence on undesirable collateral effects such as uterine and mammary tumors and nodules, Cystic endometrial hyperplasia-pyometra complex, as well as acromegaly-like lesions. In this report a 6 year -old Fox-terrier wire coat bitch is presented which was administered a depot MPA formulation in order to prevent an undesired mating-related pregnancy that was attended at the by a prolonged pregnancy at day 74 after the undesired mating. The patient showed distended abdomen, dyspnea, with no changes in hemoleukograms values, but with macerated fetuses as diagnosed by clinical and radiographic findings. An elective cesarean operation followed by ovary hysterectomy was performed. The patient showed an optimal clinical evolution. Several aspects related to the use of MPA in canine reproduction, the recommendation to cautiously prescribe its use as contraceptive agents in bitches, as well as the consideration of other alternatives for management of undesired mating in dogs, are discussed.

|Abstract
= 186 veces | PDF
= 60 veces|

Downloads

Download data is not yet available.

References

Arora N, Sandford J, Browning GF, Sandy JR, Wright PJ. A model for cystic endometrial hyperplasia/pyometra complex in the bitch. Theriogenology 2006: (en prensa)

Bhattia SFM, Rao NAS, Okkensb AC, Molb JA, Duchateau L, et. al. Role of progestin-induced mammary-derived growth hormone in the pathogenesis of cystic endometrial hyperplasia in the bitch. Domest Anim Endocrinol 2006 Agosto 10 (En prensa).

Barragry TB. Veterinary drug therapy. Lea and Fabiger. Philadelphia, 1994; capítulo 41. p1003-1020.

Beijerink NJ, Bhatti SF, Okkens AC, Dieleman SJ, Mol JA, et. al. Adenohypophyseal function in bitches treated with medroxyprogesterone acetate. Domest Anim Endocrinol 2006 Jan 18.

Beijerink NJ, Kooistra HS, Dieleman SJ, Okkens AC. Serotonin antagonist-induced lowering of prolactin secretion does not affect the pattern of pulsatile secretion of follicle-stimulating hormone and luteinizing hormone in the bitch. Reproduction 2004; 128:181-188.

Bland-van den Berg P, Bomzon L, Lurie A. Oestrogen-induced bone marrow aplasia in a dog. J S Afr Vet Assoc 1978; 49:363-365.

Bouchard GF, Solorzano N, Concannon PW, Youngquist RS, Bierschwal CJ. Determination of ovulation time in bitches based on teasing, vaginal cytology, and elisa for progesterone. Theriogenology 1991; 35:603-611.

Bowen RA, Olson PN, Behrendt MD, Wheeler SL, Husted PW, et. al. Efficacy and toxicity of estrogens commonly used to terminate canine pregnancy. J Am Vet Med Assoc 1985 15; 186:783-788.

Bryan HS. Parenteral use of medroxyprogesterone acetate as an antifertility agent in the bitch. Am J Vet Res 1973; 34:659-663 (Abstract consultado en Pubmed).

Burke TJ, Reynolds HA Jr. Megestrol acetate for estrus postponement in the bitch. J Am Vet Med Assoc 1975; 167:285-287.

Concannon P, Altszuler N, Hampshire J, Butler WR, Hansel W. Growth hormone, prolactin, and cortisol in dogs developing mammar y nodules and an acromegaly-like appearance during treatment with medroxyprogesterone acetate. Endocrinology 1980; 106:1173-1137.

Concannon PW, McCann JP, Temple M. Biology and endocrinology of ovulation, pregnancy and parturition in the dog. J Reprod Fertil Suppl 1989; 39:3-25.

Concannon PW, Spraker TR, Casey HW, Hansel W. Gross and histopathologic effects of medroxyprogesterone acetate and progesterone on the mammary glands of adult beagle bitches. Fertil Steril 1981; 36:373-387.

De Bosscher H, Ducatelle R, Tshamala M, Coryn M. Changes in sex hormone receptors during administration of progesterone to prevent estrus in the bitch. Theriogenology 2002; 58:1209-1217.

Dhaliwal GK, England GC, Noakes DE. The influence of exogenous steroid hormones on steroid receptors, uterine histological structure and the bacterial flora of the normal bitch. Anim Reprod Sci 1999; 56:259-277.

Eilts BE. Pregnancy termination in the bitch and queen. Clin Tech Small Anim Pract 2002; 17:116-123.

Feldman EC, Nelson RW. Endocrinología y reproducción en perros y gatos. 2ed. Ed Mc-Grow-Hill Interamericana. Mexico, 1996; Capítulos 17 y 18. p571-620.

Frank DW, Kirton KT, Murchison TE, Quinlan WJ, Coleman ME, et. al. Mammary tumors and serumMammary tumors and serum hormones in the bitch treated with medroxyprogesterone acetate or progesterone for four years. Fertil Steril 1979; 31:340-346.

Gobello C. Dopamine agonists, anti-progestins, anti-androgens, long-term-release GnRH agonists and anti-estrogens in canine reproduction: A review. Theriogenology 2006 (en prensa).

Goldzieher JW. Symposium on steroid hormones. 1. Synthetic progestational steroids. Their significance and use. Tex State J Med 1961; 57:962-967 (Abstract consultado en Pubmed).

Goyings LS, Sokolowski JH, Zimbelman RG, Geng S. Clinical, morphologic, and clinicopathologic findings in Beagles treated for two years with melengestrol acetate. Am J Vet Res 1977; 38:1923-1931.

Hall EJ. Use of lithium for treatment of estrogen-induced bone marrow hypoplasia in a dog. J Am Vet Med Assoc 1992; 200:814-816.

Jochle W, Lamond DR, Anderson AC. Mestranol as an abortifacient in the bitch. Theriogenology 1975; 4:1-9.

Kooistra HS, Okkens AC, Mol JA, van Garderen E, Kirpensteijn J, et. al. Lack of association of progestin-induced cystic endometrial hyperplasia with GH gene expression in the canine uterus. J Reprod Fertil Suppl. 1997; 51:355-61.

Kooistra HS, Okkens AC. Secretion of prolactin and growth hormone in relation to ovarian activity in the dog. Reprod Domest Anim 2001; 36:115-119.

Litter M. Farmacología. 6 ed. El Ateneo. Buenos Aires, 1980. Capítulo 39; p1236-1276.

Marselos M, Tomatis L. Diethylstilboestrol: II, pharmacology, toxicology and carcinogenicity in experimental animals. Eur J Cancer 1992; 29A:149-155.

McCann JP, Altszuler N, Hampshire J, Concannon PW. Growth hormone, insulin, glucose, cortisol, luteinizing hormone, and diabetes in beagle bitches treated with medroxyprogesterone acetate. Acta Endocrinol (Copenh) 1987; 116:73-80.

Nelson LW, Kelly WA. Progestogen-related gross and microscopic changes in female Beagles. Vet Pathol 1976; 13:143-156. 30. Niskanen M, Thrusfield MV. Associations between age, parity, hormonal therapy and breed, and pyometra in Finnish dogs. Vet Rec 1998; 143:493-498.

Noakes DE, Dhaliwal GK, England GC. Cystic endometrial hyperplasia/pyometra in dogs: a review of the causes and pathogenesis. J Reprod Fertil Suppl 2001; 57:395-406.

Nothling JO, Gerber D, Gerstenberg C, Kaiser C, Dobeli M. Abortifacient and endocrine effects of metergoline in beagle bitches during the second half of gestation. Theriogenology 2003; 59:1929-1940.

Owen LN, Briggs MH. Contraceptive steroid toxicology in the Beagle dog and its relevance to human carcinogenicity. Curr Med Res Opin 1976; 4:309-329.

Page SW. Diethylstilboestrol--clinical pharmacology and alternatives in small animal practice. Aust Vet J 1991; 68:226-230.

Palmer CW, Post K. Prevention of pregnancy in the dog with a combination of prostaglandin F2 alpha and bromocriptine. Can Vet J 2002; 43:460-462.

Rutteman GR, Stolp R, Rijnberk A, Loeffler S, Bakker JA, et. al. Medroxy-progesterone acetate administration to ovariohysterectomized, oestradiol-primed beagle bitches. Effect on secretion of growth hormone, prolactin and cortisol. Acta Endocrinol (Copenh) 1987; 114:275-282.

Selman PJ, Mol JA, Rutteman GR, Rijnberk A. Progestin treatment in the dog. I. Effects on growth hormone, insulin-like growth factor I and glucose homeostasis. Eur J Endocrinol 1994; 131:413-421.

Selman PJ, Mol JA, Rutteman GR, Rijnberk A. Progestin treatment in the dog. II. Effects on the hypothalamic-pituitary-adrenocortical axis. Eur J Endocrinol 1994; 131:422-430.

Selman PJ, Mol JA, Rutteman GR, van Garderen E, van den Ingh TS, et. al. Effects of progestin administration on the hypothalamic-pituitary-adrenal axis and glucose homeostasis in dogs. J Reprod Fertil Suppl. 1997; 51:345-354.

Sokolowski JH, VanRavenswaay F. Effects of melengestrol acetate on reproduction in the Beagle bitch. Am J Vet Res 1976; 37:943-945.

Stovring M, Moe L, Glattre E. A population-based case-control study of canine mammary tumours and clinical use of medroxyprogesterone acetate. APMIS 1997; 105:590-596.

Turcotte JG, Haines RF, Brody GL, Meyer TJ, Schwartz SA. Immunosuppression with medroxyprogesterone acetate. Transplantation 1968; 6:248-260.

van Os JL, Oldenkamp EP. Oestrus control in bitches with proligestone, a new progestational steroid. J Small Anim Pract 1978; 19:521-529.

van Os JL, van Laar PH, Oldenkamp EP, Verschoor JS. Oestrus control and the incidence of mammary nodules in bitches, a clinical study with two progestogens. Vet Q 1981; 3:46-56.

Von Berky AG, Townsend WL. The relationship between the prevalence of uterine lesions and the use of medroxyprogesterone acetate for canine population control. Aust Vet J 1993; 70:249-250.

Downloads

Published

2016-07-22

How to Cite

González D., M. S., & Maldonado Estrada, J. G. (2016). Gestación prolongada asociada con la prescripción inadecuada de medroxiprogesterona acetato. ¿Es racional y ético el uso de progestágenos exógenos en perras?. Revista Colombiana De Ciencias Pecuarias, 19(4), 9. https://doi.org/10.17533/udea.rccp.324103

Issue

Section

Clinical cases

Most read articles by the same author(s)

> >> 

Similar Articles

> >> 

You may also start an advanced similarity search for this article.